Sotagliflozin curbs platelet activation via dual SGLT1/2 blockade unlike empagliflozin

Michigan Medicine researchers compared sotagliflozin directly with empagliflozin in blood samples from healthy volunteers and type 2 diabetes patients plus injured-vessel mouse models. Sotagliflozin limited platelet aggregation and activation while empagliflozin showed negligible impact; genetic SGLT1 removal in platelets accounted for only 40% of the anticlotting benefit, indicating endothelial or off-target contributions.

Prior large trials including SOLOIST-WHF and SCORED already documented lower ischemic event rates with sotagliflozin versus pure SGLT2 inhibitors, yet mechanistic explanations were absent. The new data link dual inhibition to reduced platelet reactivity without full gastrointestinal toxicity seen in selective SGLT1 agents such as mizagliflozin.

Remaining questions center on whether endothelial SGLT1 blockade alters von Willebrand factor release or nitric oxide signaling in vivo. Human platelet function assays under flow conditions and imaging of microvascular thrombosis are required before attributing clinical outcome differences solely to this pathway.

Evidence calibration: These are controlled laboratory and small-animal studies demonstrating plausible mechanism; they cannot establish causality for cardiovascular event reduction or rule out confounding from glycemic or hemodynamic effects observed in prior RCTs.